Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 94 (high attention) · dilution pressure low · listing risk high · governance risk elevated · runway 2.7 mo · strongest signal: MVLS deficiency (Aug 7, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 7, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-08-07 filing | 63 |
| Aug 7, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-08-07 (accepted 17:00 ET) filing | 59 |
| Aug 7, 2026 | ▼ Equity deficiency | “stockholders equity deficiency” language in 8-K (8-K) filed 2026-08-07 filing | 52 |
| Aug 7, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-08-07 filing | 46 |
| Jul 29, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-07-29 filing | 32 |
| Jul 27, 2026 | ▼ Reverse split | “reverse split” language in 8-K/A (EX-99.3) filed 2026-07-27 filing | 32 |
| Jul 27, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-2.2) filed 2026-07-27 filing | 32 |
| Jul 27, 2026 | ▼ Going concern in 8-K | “going concern 8k” language in 8-K/A (EX-99.1) filed 2026-07-27 filing | 31 |
| Jul 23, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-K (EX-23.1) filed 2026-07-23 filing | 25 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →